Table 3.
Effectiveness of apremilast on articular manifestations.
| Baseline | M3 | M6 | EOF | |
|---|---|---|---|---|
| n | 30 | 27 | 23 | 22 |
| Complete response, n (%) | – | 17 (63) | 15 (65) | 12 (55) |
| Partial response, n (%) | – | 3 (11) | 4 (17) | 2 (9) |
| TJC, median [IQR] | 4 [2–6] | 0 [0–3] | 0 [0–2] | 0 [0–3] |
| SJC, median [IQR] | 2 [1–2] | 0 [0–0] | 0 [0–0] | 0 [0–0] |
EOF, end of follow-up; IQR, interquartile range; SJC, swollen joint count; TJC, tender joint count.